NCT06788249View on ClinicalTrials.gov

Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

March 15, 2026

Study Completion Date

April 15, 2026

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Ketamine only

The primary study intervention involves the administration of intravenous ketamine (0.5 mg/kg) over a 40-minute infusion. Ketamine, an NMDA receptor antagonist, has shown rapid antidepressant effects in individuals with treatment-resistant depression.

All Listed Sponsors
lead

University of Pennsylvania

OTHER